INVESTIGADORES
DEWEY Ricardo Alfredo
congresos y reuniones científicas
Título:
Brecept, a novel pan-TGF-β peptibody, is an effective and safe treatment for TGF-β driven diseases
Autor/es:
ANA ROMO; RICARDO A. DEWEY
Lugar:
San Francisco
Reunión:
Simposio; 3rd Annual TGF-β Summit for Immune-Oncology Drug Development.; 2023
Institución organizadora:
Hansonwade
Resumen:
Brecept, a novel pan-TGF-β peptibody, is an effective and safe treatment for TGF-β driven diseases.Ana Romo, Ricardo A. DeweyRADBIO USA, Inc., 1209 Orange St, Wilmington, Delaware, USABrecept is a 64 kDa fusion protein made up of the newly discovered TβRII-SE and the human IgG1 Fc domain. Because of a unique 13-amino acid motif at the C-terminus, TβRII-SE can bind all three TGF-β isoforms. Brecept's anti-fibrotic activity was evaluated in lung (5 and 20 mg/kg) and skin (5 mg/kg) bleomycin induced fibrosis mouse models via IV injection. Brecept was also given IV up to 50 mg/kg (once weekly for 4 weeks) in rat nonclinical toxicity tests with no cardiotoxic effects. Our findings suggest that Brecept may represent a safe and effective option to treat TGF-β related diseases.
